News for Axsome Therapeutics, Inc. (AXSM)

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ax

SAN DIEGO, April 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the

Axsome Therapeutics sees a pivotal win with its ADHD drug, solriamfetol, in Phase 3 trials. Analyst optimism remains high with an impressive average pri

**media[588926]**

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand name Sunosi) in major depressive disorder (MDD). It was a six-week proof-of-concept phase 3 trial for MDD "with and without severe excess daytime sleepiness (EDS)."

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime sleepiness. Read more here.

Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025

Axsome Therapeutics Inc (AXSM), a leader in CNS disorder treatments, announced on March 25, 2025, that its Phase 3 FOCUS trial for solriamfetol in treating ADHD

On March 6, 2025, Fairmount Funds Management LLC (Trades, Portfolio) executed a significant transaction involving Oruka Therapeutics Inc. The firm added 5,139,9

Psychedelic-assisted therapy is on the rise, and a new report confirms the rate of expansion of the psychedelic mushrooms market.

Recent Transaction Overview On February 28, 2025, SVB Capital Management, LLC (Trades, Portfolio) executed a significant transaction involving Root Inc (ROOT),

On March 5, 2025, Axsome Therapeutics Inc (AXSM), a leader in biopharmaceutical innovations for central nervous system disorders, announced a settlement agreeme

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of cen

Axsome Therapeutics said that in the FDA meeting meetings, the agency has supported a supplemental NDA submission for AXS-05 in Alzheimer’s disease agitation.

Axsome Therapeutics Inc (AXSM), a leader in biopharmaceutical innovations for central nervous system disorders, announced on March 3, 2025, that it has received

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( AXSM), a

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc.

Summary Axsome Therapeutics Inc (AXSM), a leading biopharmaceutical company focused on central nervous system (CNS) disorders, announced its participation in tw